US Plans to Bring Gilead HIV Drug to Market in High-Burden HIV Countries

US backs HIV prevention drug program despite aid cuts

INQUIRER.net WASHINGTON, United States — The United States will fund a program for affordable access to a groundbreaking HIV prevention drug in lower-income countries, the State Department said Thursday, sparing it from Donald Trump’s foreign aid blitz. Trump has thrown billions of dollars of US assistance into question since January, including for the highly popular President’s Emergency Plan for AIDS Relief (PEPFAR), which has been credited wi…

Gilead Sciences partners with Pepfar to offer HIV drug ‘at cost’

Drugmaker to supply long-acting HIV prevention drug to the Global Fund and Pepfar without profit in high-burden HIV countries, US government and company officials say

US plans to bring Gilead HIV drug to market in high-burden HIV countries

WASHINGTON (Reuters) -The U.S. State Department announced a plan on Thursday to bring Gilead Sciences Inc's drug lenacapavir to market "at cost" in high-burden HIV countries in an effort to reach two million people over three years.

The U.S. Government Announces Groundbreaking Partnership to Accelerate HIV Prevention with Innovative Lenacapavir Drug

The U.S. Government Announces Groundbreaking Partnership to Accelerate HIV Prevention with Innovative Lenacapavir Drug TOP AFRICA NEWS TOPAFRICANEWSSeptember 4, 2025 — In a major health milestone, the Department of State, Gilead Sciences,... The post The U.S. Government Announces Groundbreaking Partnership to Accelerate HIV Prevention with Innovative Lenacapavir Drug first appeared on TOP AFRICA NEWS.

US to spare HIV prevention drug program amid harsh Trump foreign assistance cuts

The US will fund a program for affordable access to a groundbreaking HIV prevention drug in lower-income countries, the State Department said Thursday.